(19)

(11)

EP 3 930 747 A1

(12)

(43) Date of publication: 05.01.2022 Bulletin 2022/01 (21) Application number: 20763489.0 (22) Date of filing: 27.02.2020

(51) International Patent Classification (IPC):  A61K 39/00(2006.01) C12N 7/00(2006.01) C07K 16/28(2006.01) (52) Cooperative Patent Classification (CPC): A61K 2039/572; A61K 2039/55533; A61K 39/00119; A61P 35/00; A61K 2039/55561; C07K 16/2818; A61K 39/3955; A01K 2207/12; A61K 2039/876; A01K 2227/105; A61K 2039/70; A61K 39/0011; A01K 2267/0331; A61K 2039/505; A61K 2039/53; A61K 39/39   C-Sets: A61K 39/00119, A61K 2300/00; A61K 39/0011, A61K 2300/00; A61K 39/3955, A61K 2300/00; (86) International application number: PCT/US2020/020224 (87) International publication number: WO 2020/176797 (03.09.2020 Gazette 2020/36)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN (30) Priority: 27.02.2019 US 201962811459 P 28.03.2019 US 201962825487 P 24.04.2019 US 201962838180 P 01.08.2019 US 201962881832 P (71) Applicants: Nektar Therapeutics San Francisco, CA 94158 (US) Vaccibody AS 0349 Oslo (NO)

(72) Inventors: ZALEVSKY, Jonathan Berkeley, CA 94705 (US) FREDRIKSEN, Agnete Brunsvik 2005 Raelingen (NO) AXELSEN, Mads 2830 Virum (DK) SCHJETNE, Karoline 1350 Lommedalen (NO) (74) Representative: D Young & Co LLP  120 Holborn London EC1N 2DY London EC1N 2DY (GB)